Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study.
Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when treated with durvalumab, and were more likely to still be alive two years after treatment.
